High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma

High-dose ipilimumab (IPI) and high-dose interleukin-2 (IL-2) are approved agents for metastatic melanoma, but the efficacy and safety of the combination are unknown. The objective of this study was to evaluate the feasibility, safety, and efficacy of combination high-dose IPI and high-dose IL-2 in...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Front Oncol
Autori principali: Silk, Ann W., Kaufman, Howard L., Curti, Brendan, Mehnert, Janice M., Margolin, Kim, McDermott, David, Clark, Joseph, Newman, Jenna, Bommareddy, Praveen K., Denzin, Lisa, Najmi, Saltanat, Haider, Azra, Shih, Weichung, Kane, Michael P., Zloza, Andrew
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2020
Soggetti:
Oncology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6965158/
https://ncbi.nlm.nih.gov/pubmed/31998643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.01483
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi